Stockscreener 앱 받기
78.11
3.86%
2.90
시간 외 거래:
78.11
전일 마감가:
$75.21
열려 있는:
$75.8
하루 거래량:
3.34M
Relative Volume:
1.42
시가총액:
$10.61B
수익:
$105.82M
순이익/손실:
$-829.61M
주가수익비율:
-11.41
EPS:
-6.8429
순현금흐름:
$-548.92M
1주 성능:
+16.46%
1개월 성능:
+2.98%
6개월 성능:
+30.58%
1년 성능:
+140.04%
1일 변동 폭
$75.75
$79.30
1주일 범위
$67.45
$79.30
52주 변동 폭
$31.99
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
78.11 | 9.69B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Wells Fargo | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade - Stock Titan
Cytokinetics, Inc. (CYTK) Stock Analysis: Tapping into a Potential 49% Upside in the Biotech Sector - DirectorsTalk Interviews
Cytokinetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $106.58, Implies 52% Upside - TradingView
Monashee Investment Management LLC Sells 25,000 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Acquired by GW&K Investment Management LLC - MarketBeat
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics EVP Malik sells $237,930 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $237,930 in shares - Investing.com India
Cytokinetics (CYTK) EVP exercises options and sells 3,500 shares - Stock Titan
Nonprofits can seek up to $20K from Cytokinetics for health equity - Stock Titan
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK) - Yahoo Finance
807,070 Shares in Cytokinetics, Incorporated $CYTK Acquired by Norges Bank - MarketBeat
Cytokinetics, Inc. (CYTK) Stock Analysis: A Promising Biotech Player with Potential 46.47% Upside - DirectorsTalk Interviews
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program - Yahoo Finance
Cytokinetics, Incorporated $CYTK Stake Trimmed by TD Asset Management Inc - MarketBeat
Total liabilities & shareholders' equities of Cytokinetics, Incorporated – XETR:KK3A - TradingView
CYTK Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Power Value - newsline.com
Long term debt to total assets ratio of Cytokinetics, Incorporated – XETR:KK3A - TradingView
ETFs Investing in Cytokinetics, Incorporated Stocks - TradingView
Cytokinetics, Incorporated Trade Ideas — XETR:KK3A - TradingView
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Truist raises Cytokinetics stock price target on positive trial data - Investing.com
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics Inc (CYTK) News, Articles, Events & Latest Updates - Stocktwits
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report? - Yahoo Finance
BNP Paribas Financial Markets Purchases 332,397 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics director Parshall sells $370,400 of CYTK stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics EVP Andrew Callos sells $1.11m in stock By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics director Edward Kaye sells $223,171 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.11m in stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares - Investing.com
Cytokinetics director Parshall sells $370,400 of CYTK stock - Investing.com
Cytokinetics (CYTK) director Kaye sells 2,933 shares at $76.09 - Stock Titan
CYTOKINETICS (CYTK) CCO exercises options and sells 15,000 shares at $74.08 - Stock Titan
Director Parshall trims Cytokinetics (CYTK) stake with 5,000-share sale - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics (CYTK) Launches Myqorzo in Germany for Heart Condition Treatment - GuruFocus
Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy - marketscreener.com
Cytokinetics launches heart drug Myqorzo in Germany By Investing.com - Investing.com Australia
Cytokinetics launches heart drug Myqorzo in Germany - Investing.com
Cytokinetics Announces European Launch of MYQORZO® (aficamten) for Obstructive Hypertrophic Cardiomyopathy in Germany Following U.S. Approval - Quiver Quantitative
Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany - marketscreener.com
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany - The Manila Times
New heart drug MYQORZO reaches German patients with obstructive HCM - Stock Titan
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytokinetics Inc 주식 (CYTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jun 09 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Jun 09 '26 |
Sale |
67.98 |
3,500 |
237,930 |
153,902 |
| Kaye Edward M. MD | Director |
Jun 01 '26 |
Sale |
76.09 |
2,933 |
223,172 |
10,283 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jun 01 '26 |
Option Exercise |
23.26 |
15,000 |
348,900 |
73,555 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jun 01 '26 |
Sale |
74.08 |
15,000 |
1,111,200 |
58,555 |
| PARSHALL B LYNNE | Director |
Jun 01 '26 |
Sale |
74.08 |
5,000 |
370,400 |
15,784 |
2.60%
0.94%
자본화:
|
볼륨(24시간):